General Information of Drug Therapeutic Target (DTT) (ID: TT2GM5R)

DTT Name Lymphocyte activation antigen CD30 (TNFRSF8)
Synonyms Tumor necrosis factor receptor superfamily member 8; KI-1 antigen; D1S166E; CD30L receptor; CD30
Gene Name TNFRSF8
DTT Type
Successful target
[1]
UniProt ID
TNR8_HUMAN
TTD ID
T88023
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MRVLLAALGLLFLGALRAFPQDRPFEDTCHGNPSHYYDKAVRRCCYRCPMGLFPTQQCPQ
RPTDCRKQCEPDYYLDEADRCTACVTCSRDDLVEKTPCAWNSSRVCECRPGMFCSTSAVN
SCARCFFHSVCPAGMIVKFPGTAQKNTVCEPASPGVSPACASPENCKEPSSGTIPQAKPT
PVSPATSSASTMPVRGGTRLAQEAASKLTRAPDSPSSVGRPSSDPGLSPTQPCPEGSGDC
RKQCEPDYYLDEAGRCTACVSCSRDDLVEKTPCAWNSSRTCECRPGMICATSATNSCARC
VPYPICAAETVTKPQDMAEKDTTFEAPPLGTQPDCNPTPENGEAPASTSPTQSLLVDSQA
SKTLPIPTSAPVALSSTGKPVLDAGPVLFWVILVLVVVVGSSAFLLCHRRACRKRIRQKL
HLCYPVQTSQPKLELVDSRPRRSSTQLRSGASVTEPVAEERGLMSQPLMETCHSVGAAYL
ESLPLQDASPAGGPSSPRDLPEPRVSTEHTNNKIEKIYIMKADTVIVGTVKAELPEGRGL
AGPAEPELEEELEADHTPHYPEQETEPPLGSCSDVMLSVEEEGKEDPLPTAASGK
Function May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. Receptor for TNFSF8/CD30L.
KEGG Pathway
Cytokine-cytokine receptor interaction (hsa04060 )
Reactome Pathway
TNFs bind their physiological receptors (R-HSA-5669034 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Brentuximab vedotin DMWLC57 Hodgkin lymphoma 2B30 Approved [1]
------------------------------------------------------------------------------------
20 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
AFM13 DMN45IC Hodgkin lymphoma 2B30 Phase 2 [2]
CAR-T cells targeting CD30 DML0KWM Non-hodgkin lymphoma 2B33.5 Phase 2 [3]
Iratumumab DMI874B Lymphoma 2A80-2A86 Phase 2 [4]
SGN-30 DMJ9M5D Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
TT11X DMW3M7X Hodgkin lymphoma 2B30 Phase 2 [6]
TT20X DMHGI09 Aggressive cancer 2A00-2F9Z Phase 2 [6]
4SCAR19 and 4SCAR30 DMUYFS1 B-cell lymphoma 2A86 Phase 1/2 [7]
Anti-CD30 CAR T cells DM8139V Lymphoma 2A80-2A86 Phase 1/2 [8]
Anti-CD30-CAR-transduced T cells DMTZSPJ leukaemia 2A60-2B33 Phase 1/2 [9]
CAR.CD30 cells DM6ZXWY Immune System disease 4A01-4B41 Phase 1/2 [10]
CART30 DMLE8T9 Hodgkin lymphoma 2B30 Phase 1/2 [11]
Anti-CD30 CAR-T cells DMTK78L leukaemia 2A60-2B33 Phase 1 [12]
Anti-CD30-CAR T cells DM2IEB7 Hodgkin lymphoma 2B30 Phase 1 [13]
ATLCAR.CD30 cells DMZI4UX Immune System disease 4A01-4B41 Phase 1 [14]
ATLCAR.CD30.CCR4 cells DM3IPSX Immune System disease 4A01-4B41 Phase 1 [14]
CAR CD30 T cells DM8NLPI Hodgkin lymphoma 2B30 Phase 1 [15]
CD30 CAR T Cells DM4VCJA Hodgkin lymphoma 2B30 Phase 1 [16]
ICAR30 T cells DM3YZCV Anaplastic large cell lymphoma 2A90.A Phase 1 [17]
SGN-CD30C DMKW10G Lymphoma 2A80-2A86 Phase 1 [18]
Xmab-2513 DM6V0KY Lymphoma 2A80-2A86 Phase 1 [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 Clinical Trial Drug(s)
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ber-H2/saporin DMXRTFM N. A. N. A. Terminated [20]
------------------------------------------------------------------------------------
2 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
H22xKi-4 DMOJI0N Discovery agent N.A. Investigative [21]
VT-362 DMG1Q0W Autoimmune diabetes 5A10 Investigative [22]
------------------------------------------------------------------------------------

References

1 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
2 Clinical pipeline report, company report or official report of Affimed Therapeutics.
3 ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
4 Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol. 2012; 5(Suppl 1): A2.
5 The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42.
6 Clinical pipeline report, company report or official report of Tessa Therapeutics
7 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
8 ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
9 ClinicalTrials.gov (NCT02958410) A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
10 ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
11 ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
12 ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
13 ClinicalTrials.gov (NCT03049449) T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
14 ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
15 ClinicalTrials.gov (NCT01316146) Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
16 ClinicalTrials.gov (NCT02917083) CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
17 ClinicalTrials.gov (NCT03383965) CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
18 Clinical pipeline report, company report or official report of Seagen.
19 Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol (Meeting Abstracts) May 2009 vol. 27 no. 15S 8531.
20 Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood. 1995 Apr15;85(8):2139-46.
21 Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002 Nov 1;100(9):3101-7.
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1877).